Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer

Amivantamab (Rybrevant, Johnson & Johnson) plus lazertinib (Lazcluze, Johnson & Johnson) is indicated 'for the first‑line treatment of adult patients with advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations'.

The dosage schedules are available in:

• the summary of product characteristics for the intravenous formulation of amivantamab

• the summary of product characteristics for the subcutaneous formulation of amivantamab and

• the summary of product characteristics for lazertinib.

The prices of the intravenous formulation of amivantamab is £1,079 for a 350 mg per 7‑ml vial (excluding VAT; BNF online accessed June 2025). The price of the subcutaneous formulation of amivantamab is £3,237 for 1,600 mg per 10-ml vial (excluding VAT; company submission). The price of lazertinib is £4,128.50 for 56 x 80‑mg tablets, and £6,192.75 for 28 x 240‑mg tablets (company submission).

The company has commercial arrangements for amivantamab and lazertinib. These make amivantamab and lazertinib available to the NHS with discounts. The sizes of the discounts are commercial in confidence.

For information, the Carbon Reduction Plan for UK carbon emissions is published on Johnson & Johnson Innovative Medicine's webpage on their responsibility to the planet.